Dual Vaccine Trial in Myeloproliferative Neoplasms
Status:
Recruiting
Trial end date:
2022-07-10
Target enrollment:
Participant gender:
Summary
A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1
peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to
vaccination and subsequently safety, toxicity and clinical effect.